Transplant Genomics Announces Collaboration with Astellas
News May 11, 2016
Transplant Genomics® has announced that they have signed a laboratory services agreement with Astellas Pharma Global Development, Inc. Under terms of the agreement, Astellas will provide Transplant Genomics with funding and blood samples from renal transplant patients collected as part of a two year, prospective, randomized, multi-center clinical trial examining surrogate markers for long-term kidney transplant outcomes while comparing two immunosuppressive agents.
The primary outcome measure in the study is a composite endpoint combining the incidence of de novo donor specific antibodies (DSA) and molecular phenotyping using Transplant Genomics’ TruGraf™ test. Transplant Genomics will provide real-time molecular analysis of blood samples collected during the trial using TruGraf™, which will measure molecular signatures of immune activation in renal transplant patients.
“As Astellas is a worldwide leader in the development and commercialization of therapeutics for transplantation, we are excited to participate in this opportunity. TruGraf’s ability to measure subclinical acute rejection as well as clinical acute rejection will provide an enabling metric to compare immunosuppressive performance,” said Dr. Roy First, Chief Medical Officer, Transplant Genomics.
Astellas has designed a prospective, randomized, controlled clinical trial comparing two immunosuppressive agents, designed to detect a difference in surrogate markers of chronic immune-mediated graft loss: DSA and real-time molecular profiling (TruGraf) testing in peripheral blood samples from individual patients. These two components will be combined as part of a dual composite endpoint designed to test the hypothesis that the consistency of immunosuppression with Astagraf XL® decreases the development of DSA and reduces the molecular signature of immune activation.
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Microbiotica Enters into Microbiome Collaboration with GenentechNews
Strategic collaboration for microbiome biomarker signatures and therapeutic discovery based on Genentech’s inflammatory bowel disease pipeline.READ MORE